title: Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.
abstract: OBJECTIVE
  Summarize current knowledge, critical gaps in knowledge, and recommendations to advance the field of metastatic bone cancer.
  
  
  METHODS
  A multidisciplinary consensus conference was convened to review recent progress in basic and clinical research, assess critical gaps in current knowledge, and prioritize recommendations to advance research in the next 5 years. The program addressed three principal topics: biology of metastasis, preserving normal bone health, and optimizing bone-targeted therapies.
  
  
  RESULTS
  A variety of specific recommendations were identified as important to advance research and clinical care over the next 5 years.
  
  
  CONCLUSIONS
  Priorities for research in bone biology include characterizing components of the stem cell niche in bone, developing oncogenic immunocompetent animal models of bone metastasis, and investigating the unique contribution of the bone microenvironment to tumor growth and dormancy. Priorities for research in preserving normal bone health include developing methods to measure and characterize disseminating tumor cells, assessing outcomes from the major prevention trials currently in progress, and improving methodologies to assess risks and benefits of treatment. Priorities for optimizing bone-targeted therapies include advancing studies of serum proteomics and genomics to reliably identify patients who will develop bone metastases, enhancing imaging for early detection of bone metastases and early response evaluation, and developing new tests to evaluate response to bone-directed treatments.
authors.affiliation: The University of Sheffield Cancer Research Centre, Sheffield, UK. r.e.coleman@sheffield.ac.uk
authors.forename: Robert E
authors.initials: RE
authors.lastname: Coleman
authors.forename: Theresa A
authors.initials: TA
authors.lastname: Guise
authors.forename: Allan
authors.initials: A
authors.lastname: Lipton
authors.forename: G David
authors.initials: GD
authors.lastname: Roodman
authors.forename: James R
authors.initials: JR
authors.lastname: Berenson
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Body
authors.forename: Brendan F
authors.initials: BF
authors.lastname: Boyce
authors.forename: Laura M
authors.initials: LM
authors.lastname: Calvi
authors.forename: Peyman
authors.initials: P
authors.lastname: Hadji
authors.forename: Eugene V
authors.initials: EV
authors.lastname: McCloskey
authors.forename: Fred
authors.initials: F
authors.lastname: Saad
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Smith
authors.forename: Larry J
authors.initials: LJ
authors.lastname: Suva
authors.forename: Russell S
authors.initials: RS
authors.lastname: Taichman
authors.forename: Robert L
authors.initials: RL
authors.lastname: Vessella
authors.forename: Katherine N
authors.initials: KN
authors.lastname: Weilbaecher
mesh_terms: D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D006801:Humans; D017410:Practice Guidelines as Topic